Reduced Intensity-New York Medical College-Leukemia-Lymphoma-Bone Marrow Failure-Immunodeficiencies-Histiocytosis-Sickle Cell Disease-Beta Thalassemia-Inborn Errors of Metabolism

This refers to a specific reduced-intensity conditioning (RIC) regimen developed and evaluated by New York Medical College for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The regimen is designed for children, adolescents, and young adults with various malignant (e.g., leukemia, lymphoma) and non-malignant (e.g., sickle cell disease, thalassemia, bone marrow failure) conditions. The standard RIC protocol in this context typically involves a combination of busulfan, fludarabine, and alemtuzumab, followed by the infusion of CD34+ selected stem cells from partially matched family or matched unrelated donors. The goal of this approach is to achieve stable engraftment while minimizing the risk of severe graft-versus-host disease (GVHD) and transplant-related toxicity through T-cell depletion and tacrolimus-based immunosuppression.

Other names

NYMC RIC ProtocolReduced Intensity Conditioning NYMCCD34+ Selection in Allogeneic Stem Cell Transplantation (Reduced Intensity Arm)